Understanding functional dyspepsia and its subtypes and the role of prokinetics in its management: a cross-sectional clinician-based survey

Authors

  • Shrikant Mukewar Midas Multispeciality Hospital Pvt. Ltd., Central Bazar Road, Ramdaspeth, Nagpur, Maharashtra, India
  • Nitesh Pratap Krishna Institute of Medical Sciences (KIMS) Limited, Begumpet, Secunderabad, Telangana, India
  • Samit Jain Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20233520

Keywords:

Functional dyspepsia, Postprandial fullness, Itopride, Proton pump inhibitors, Prokinetics

Abstract

Background: This survey evaluated opinions of consulting physicians or gastroenterologists on functional dyspepsia (FD) in the Indian population and the management of FD with prokinetics, especially itopride.

Methods: A total of 243 clinicians involved in the clinical practice of FD were invited to complete an internet-based, structured survey questionnaire. Questionnaire comprised 29 questions on the diagnosis and treatment options for FD.

Results: Majority of the clinicians opined that females were more affected by FD than males in both hospital-based (53.4%) and community-based (56.6%) practices. As per 33.3% of clinicians each, the age group of 21-40 years and 41-60 years were the two most commonly affected groups. FD symptoms were present for >6 months before patients seek consultation as reported by 62.6% of the clinicians. The participating clinicians preferred using detailed patient history (77.7%) and ROME IV criteria (71.1%) for diagnosing FD. Prokinetics were regarded as the therapy of choice primarily because of their efficacy in reducing FD symptoms. Among all prokinetics used, itopride was most preferred for postprandial distress syndrome (64.2% clinicians) and for epigastric pain syndrome in combination with PPIs (66.7% clinicians). Itopride was reported by 93.6% clinicians to be well tolerated, with the leading advantage being absence of extrapyramidal or cardiac side effects according to 40% of clinicians.

Conclusions: The clinicians considered itopride to be most preferred to reduce FD symptoms and to be well-tolerated when taken alone or in combination with PPIs.

References

Shi X, Luo H, Wang X, Ren G, Zhang L, Tao Q et al. Functional dyspepsia symptom diary is correlated with other questionnaires and associated with severity in patients with functional dyspepsia: a multicenter, prospective observational study. J Gastroenterol Hepatol. 2022;37(7):1298-306.

Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut. 2015;64(7):1049-57.

Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.

Mannava AK, Kumar U. Prevalence of functional dyspepsia in a Rural Medical College Hospital. J Evolution Med Dental Sci. 2014;3(8):1934-40.

Mahadeva S, Goh KL. Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol. 2006; 12(17):2661.

Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol. 1998;93(10):1816-22.

Rane SV, Asgaonkar B, Rathi P, Contractor Q, Chandnani S, Junare P et al. Effect of moderate aerobic exercises on symptoms of functional dyspepsia. Indian J Gastroenterol. 2021;40(2):189-97.

Goyal O, Nohria S, Dhaliwal AS, Goyal P, Soni RK, Chhina RS, et al. Prevalence, overlap, and risk factors for Rome IV functional gastrointestinal disorders among college students in northern India. Indian J Gastroenterol. 2021;40:144-53.

Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380-92.

Mahadeva S, Yadav H, Rampal S, Goh KL. Risk factors associated with dyspepsia in a rural Asian population and its impact on quality of life. Am J Gastroenterol. 2010;105(4):904-12.

Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8(10):830-37.

Madisch A, Andresen V, Enck P, Labenz J, Frieling T, Schemann M. The diagnosis and treatment of functional dyspepsia. Dtsch Ärztebl Int. 2018;115(13):222-32.

Tack J, Bisschops RA, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology. 2004;127(4):1239-55.

Ghoshal UC, Singh R. Functional dyspepsia: the Indian scenario. J Assoc Physicians India. 2012;60:6-8.

Enck P, Azpiroz F, Boeckxstaens G, Elsenbruch S, Feinle-Bisset C, Holtmann G, et al. Functional dyspepsia. Nat Rev Dis Primers. 2017;3(1):1-20.

Vakil NB, Howden CW, Moayyedi P, Tack J. White paper AGA: Functional dyspepsia. Clin Gastroenterol Hepatol. 2017;15(8):1191-1194.

Yin J, Chen JD. Electrogastrography: methodology, validation and applications. J Neurogastroenterol Motil. 2013;19(1):5-17.

Addula M, Wilson VE, Reddymasu S, Agrawal DK. Immunopathological and molecular basis of functional dyspepsia and current therapeutic approaches. Expert Rev Clin Immunol. 2018;14(10):831-40.

Koduru P, Irani M, Quigley EM. Definition, pathogenesis, and management of that cursed dyspepsia. Clin Gastroenterol Hepatol. 2018;16(4):467-79.

Vanheel H, Tack J. Therapeutic options for functional dyspepsia. Dig Dis. 2014;32(3):230-34.

Fraser A, Delaney BC, Ford AC, Qume M, Moayyedi P. The short‐form leeds dyspepsia questionnaire validation study. Aliment Pharmacol Ther. 2007;25(4):477-86.

Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. New Engl J Med. 2006;354(8):832-40.

Miwa H, Ghoshal UC, Gonlachanvit S, Gwee KA, Ang TL, Chang FY et al. Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil. 2012;18(2):150-68.

Anthoine E, Moret L, Regnault A, Sébille V, Hardouin JB. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes. 2014;12:176.

Alwhaibi A, Alghadeer S, Bablghaith S, Wajid S, Alrabiah Z, Alhossan A, et al. Prevalence and severity of dyspepsia in Saudi Arabia: A survey-based study. Saudi Pharm J. 2020;28(9):1062-7.

Kim SE, Park HK, Kim N, Joo YE, Baik GH, Shin JE et al. Prevalence and risk factors of functional dyspepsia: a nationwide multicenter prospective study in Korea. J Clin Gastroenterol. 2014;48(2):e12-8.

Wauters L, Dickman R, Drug V, Mulak A, Serra J, Enck P et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. Neurogastroenterol Motil. 2021;33(9):e14238.

Saxena GN, Mathur S. A randomized controlled study of efficacy and safety profile of levosulpiride and itopride in functional dyspepsia. J Mahatma Gandhi Univ Med Sci Tech. 2020;5(2):50-6.

Zhang CX, Guo LK. Dalitong granule combined with electroacupuncture in the treatment of functional dyspepsia: a randomized controlled trial. Chin J Integr Med. 2015;21:743-50.

Huang X, Lv B, Zhang S, Fan YH, Meng LN. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol. 2012;18(48):7371-7.

Kamiya T, Shikano M, Kubota E, Mizoshita T, Wada T, Tanida S et al. A multicenter randomized trial comparing rabeprazole and itopride in patients with functional dyspepsia in Japan: the NAGOYA study. J Clin Biochem Nutrition. 2017;60(2):130-5.

Pinto‐Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11(11):CD011194.

Cheddie S, Manneh CG, Owczarek BM, Moodley Y. Age is a predictor of significant endoscopic findings in dyspepsia patients in South Africa. S Afr J Surg. 2020;58(1):14-7.

Oh JH, Kwon JG. Functional dyspepsia. Korean J Gastroenterol. 2019;73(2):77-83.

Talley NJ, Tack J, Ptak T, Gupta R, Giguere M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut. 2008;57(6):740-6.

Biswas M, Singh KM, Shetty YC, Koli PG, Ingawale S, Bhatia SJ. Prescription pattern and adverse drug reactions of prokinetics. Indian J Med Res. 2019;149:748-54.

Joe J. Levosulpiride-Induced Neurological Adverse Effects: A prospective study from a tertiary care center. Ann Indian Acad Neurol. 2020;23(2):174-6.

Downloads

Published

2023-11-07

Issue

Section

Original Research Articles